Literature DB >> 9842637

Incidence and pattern of liver involvement in haematological malignancies.

R Walz-Mattmüller1, H P Horny, P Ruck, E Kaiserling.   

Abstract

The incidence and pattern of liver involvement in 127 liver specimens (2 biopsy and 125 autopsy specimens) from cases of acute myelogenous leukaemia (25), chronic myelogenous leukaemia (7), acute lymphatic leukaemia (5), chronic lymphatic leukaemia (9), multiple myeloma (25), low-grade non-Hodgkin's lymphoma (25), high-grade non-Hodgkin's lymphoma (24) and myeloproliferative diseases (7) were investigated histologically and immunohistochemically. Liver infiltration was found frequently in chronic leukaemia and myeloproliferative diseases (80-100%), acute leukaemia (60-70%) and non-Hodgkin's lymphoma (50-60%), but was significantly less common in multiple myeloma (32%) than in any of the other diagnostic groups. Hepatomegaly was found in over 50% of cases in all the diagnostic groups, but was not always associated with infiltration. Diffuse, non-destructive infiltration was most common: in acute myelogenous leukaemia, both the portal triads and sinusoids were usually involved; in chronic myelogenous leukaemia, multiple myeloma and myeloproliferative diseases, infiltration was mainly sinusoidal; and in lymphatic leukaemia and non-Hodgkin's lymphoma the portal triads were mainly involved. Nodular infiltration was seen in multiple myeloma and non-Hodgkin's lymphoma. The primary tumours and liver infiltrates generally exhibited the same immunophenotype, although reactivity with the antibody L26 (CD20) was only found in the primary lesion in many high-grade B-cell lymphomas. Thus, liver involvement is common in haematological malignancies, but the incidence and pattern of infiltration vary amongst the different types.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9842637     DOI: 10.1016/S0344-0338(98)80068-X

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  14 in total

1.  [Ultrasound in the diagnostic management of malignant lymphomas].

Authors:  H-P Weskott
Journal:  Radiologe       Date:  2012-04       Impact factor: 0.635

2.  Amyloidosis and subacute liver failure.

Authors:  Moby Joseph; Timothy J S Cross
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-03

Review 3.  [Malignant lymphomas of the liver: new diagnostic algorithms].

Authors:  T Longerich; P Schirmacher; H P Dienes; H Stein; C Loddenkemper
Journal:  Pathologe       Date:  2006-07       Impact factor: 1.011

4.  [Pathology along the liver sinusoids: intrasinusoidal findings].

Authors:  U Flucke; H-P Fischer
Journal:  Pathologe       Date:  2008-02       Impact factor: 1.011

Review 5.  The use of novel agents in multiple myeloma patients with hepatic impairment.

Authors:  Lindsay C Stansfield; Wilson I Gonsalves; Francis K Buadi
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

6.  Hepatic failure caused by plasma cell infiltration in multiple myeloma.

Authors:  Fadi-E Rahhal; Robert-R Schade; Asha Nayak; Teresa A Coleman
Journal:  World J Gastroenterol       Date:  2009-04-28       Impact factor: 5.742

7.  Nodular liver lesions involving multiple myeloma: a case report and literature review.

Authors:  Xiao-Ning Wu; Xin-Yan Zhao; Ji-Dong Jia
Journal:  World J Gastroenterol       Date:  2009-02-28       Impact factor: 5.742

8.  T cell prolymphocytic leukemia: a rare cause of acute liver failure.

Authors:  David P McElreath; Terence L Angtuaco; Brent Staggs; Arshad H Malik
Journal:  Dig Dis Sci       Date:  2006-04       Impact factor: 3.487

9.  Frequency and diagnostic patterns of lymphomas in liver biopsies with respect to the WHO classification.

Authors:  Christoph Loddenkemper; Thomas Longerich; Michael Hummel; Karen Ernestus; Ioannis Anagnostopoulos; Hans-Peter Dienes; Peter Schirmacher; Harald Stein
Journal:  Virchows Arch       Date:  2007-03-13       Impact factor: 4.064

10.  Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival.

Authors:  Takayoshi Kiba; Takuo Ito; Toshihisa Nakashima; Yoshiko Okikawa; Miki Kido; Akiko Kimura; Keita Kameda; Fumiaki Miyamae; Suzuko Tanaka; Misao Atsumi; Yoko Sumitani; Yoshimi Shitakubo; Hiromasa Niimi
Journal:  BMC Cancer       Date:  2014-06-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.